Aarey Drugs & Pharmaceuticals Fair Value
Aarey Drugs & Pharmaceuticals (AAREYDRUGS) average fair value is ₹166.45 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹95.19 (+74.86%), fair value range ₹21.39–₹613.15. Also explore AAREYDRUGS price trends to track price trends across different timeframes.
Fair Value Analysis Export
AAREYDRUGS Fair Value vs Current Price — Valuation Summary
AAREYDRUGS average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). See Aarey Drugs & Pharmaceuticals P/B ratio trends to compare market price against book value per share.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
AAREYDRUGS Fair Value Analysis — Data Sources & Coverage
Aarey Drugs & Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit Aarey Drugs & Pharmaceuticals share price screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
AAREYDRUGS vs Healthcare Sector Peers — P/E, P/B & Market Cap
Aarey Drugs & Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Aurobindo Pharma | AUROPHARMA | 25.16 | 2.5 | ₹87,806 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.